HRP20190805T1 - Spojevi triazolopirimidina i njihova uporaba - Google Patents

Spojevi triazolopirimidina i njihova uporaba Download PDF

Info

Publication number
HRP20190805T1
HRP20190805T1 HRP20190805TT HRP20190805T HRP20190805T1 HR P20190805 T1 HRP20190805 T1 HR P20190805T1 HR P20190805T T HRP20190805T T HR P20190805TT HR P20190805 T HRP20190805 T HR P20190805T HR P20190805 T1 HRP20190805 T1 HR P20190805T1
Authority
HR
Croatia
Prior art keywords
alkyl
independently selected
compound
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
HRP20190805TT
Other languages
English (en)
Inventor
Ho Man Chan
Xiang-Ju Justin Gu
Ying Huang
Ling Li
Yuan Mi
Wei Qi
Martin Sendzik
Yongfeng SUN
Long Wang
Zhengtian Yu
Hailong Zhang
Ji Yue Zhang (Jeff)
Man ZHANG
Qiong Zhang
Kehao Zhao
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of HRP20190805T1 publication Critical patent/HRP20190805T1/hr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Claims (27)

1. Spoj, naznačen time, što je predstavljen Formulom (I): ili njegova farmaceutski prihvatljiva sol, u kojoj: je jednostruka veza ili dvostruka veza; R1 i R2 su neovisno H ili halogen; R3 je neovisno odabran od: halogena, fenila i 5-članog do 6-članog heteroarila koji obuhvaća ugljikove atome i 1-4 heteroatoma koji su odabrani od N, NRa, O i S(O)p; pri čemu su navedeni fenil i heteroaril supstituirani s 0-3 R3A; svaki R3A je neovisno odabran od: halogena, CN, -(O)m-(C1-C6 alkila supstituiranog s 0-1 R3B), C1-C6 haloalkila, C1-C6 haloalkoksi, R3C, -OR3C, -C(=O)R3D, NR3ER3F, -C(=O)NR3ER3F, -NHC(=O)R3D, -S(=O)2R3D, -S(=O)2NR3ER3F, -NHS(=O)2(C1-C4 alkil) i -CR3CR3ER3G; R3B je neovisno odabran od: OH, NReRf, C1-C4 alkoksi, -C(=O)NReRf, -S(=O)2(C1-C4 alkil), -NHC(=O)(C1-C4 alkil), i 5-članog do 6-članog heterocikloalkila koji obuhvaća ugljikove atome i 1-2 heteroatoma koji su odabrani od N, NRa, O, i S(O)p; pri čemu je navedeni heterocikloalkil supstituiran s 0-2 RC; svaki R3C je neovisno odabran od: C3-C6 cikloalkila, fenila, i 4-članog do 7-članog heterocikla koji obuhvaća ugljikove atome i 1-4 heteroatoma koji su odabrani od N, NRa, O, i S(O)p; pri čemu je svaki dio skupine supstituiran s 0-2 Rc; svaki R3D je neovisno odabran od: C1-C4 alkil i R3C; R3E i R3G su, pri svakoj pojavi, neovisno odabrani od: H i C1-C4 alkila; svaki R3F je neovisno odabran od: H i C1-C4 alkila supstituiranog s 0-1 Rd; R4 je neovisno odabran od: H, halogena i C1-C4 alkila; R5 je neovisno odabran od OH i C1-C4 alkila; svaki Ra je neovisno odabran od: H, →O, C1-C4 alkila supstituiranog s 0-1 Rb, -C(=O)H, -C(=O)(C1-C4 alkila), -CO2(C1-C4 alkila), C3-C6 cikloalkila, i benzila; Rb je neovisno odabran od: halogena, OH i C1-C4 alkoksi; [0001] svaki Rc je neovisno odabran od: =O, halogena, OH, C1-C4 alkila, C1-C4 haloalkila, C1-C4 alkoksi, i C1-C4 haloalkoksi; Rd je neovisno odabran od: OH i NReRf; Re i Rf su, pri svakoj pojavi, neovisno odabrani od: H i C1-C4 alkila; svaki p je neovisno odabran od 0, 1 i 2; i m i n su, pri svakoj pojavi, neovisno odabrani od 0 i 1.
2. Spoj ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, naznačen time, što: [0002] svaki R3A je neovisno odabran od: halogena, CN, -(O)m-(C1-C4 alkila supstituiranog s 0-1 R3B), C1-C4 haloalkila, C1-C4 haloalkoksi, R3C, -C(=O)R3D, NR3ER3F, [0003] -C(=O)NR3ER3F, -S(=O)2R3D, -S(=O)2NHR3F, -NHS(=O)2(C1-C4 alkil), [0004] -O-C3-C6 cikloalkila, i [0005] ; Ra je neovisno odabran od: H, →O, C1-C4 alkila supstituiranog s 0-1 Rb, -C(=O)H, -C(=O)(C1-C4 alkila), -CO2(C1-C4 alkila), i C3-C6 cikloalkila; R4 je H; m je neovisno odabran od 0 i 1; i n je 0.
3. Spoj ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1 ili zahtjevu 2, naznačen time, što: R1 je neovisno H ili F; R2 je H; i R3 je neovisno odabran od: fenila, i 6-članog heteroarila koji obuhvaća ugljikove atome i 1-2 heteroatoma koji su odabrani od N i NRa; pri čemu su navedeni fenil i heteroaril supstituirani s 0-3 R3A.
4. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 3, naznačen time, što: R3 je neovisno odabran od: fenila, piridila, pirimidila, piridazinila i pirazinila; pri čemu je svaki dio skupine supstituiran s 0-3 R3A.
5. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 4, naznačen time, što: R3 je neovisno odabran od: i .
6. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 4, naznačen time, što: R3 je neovisno odabran od: i [0006] ; svaki R3A je neovisno odabran od: halogena, CN, -(O)m-(C1-C4 alkila supstituiranog s 0-1 R3B), C1-C4 haloalkila, C1-C4 haloalkoksi, -C(=O)NH2, -C(=O)NH(C1-C4 alkila), -C(=O)N(C1-C4alkila)2, -C(=O)N(C1-C4alkil)(CH2)2N(C1-C4 alkila)2, -CH2NHC(=O)(C1-C4 alkila), -S(=O)2R3D, -S(=O)2NH(C1-C4 alkila supstituiranog s 0-1 OH), -NHS(=O)2(C1-C4 alkila), NH2, -NH(C1-C4 alkila), -N(C1-C4 alkila)2, C3-C6 cikloalkila,
i [0007] ; R3B je neovisno odabran od: OH, NH2, NH(C1-C4 alkila), N(C1-C4 alkila)2, C1-C4 alkoksi, -C(=O)N(C1-C4 alkila)2, -S(=O)2(C1-C4 alkila),
i ; R3D je neovisno odabran od: C1-C4 alkila i 1H-piperidin-4-ila; i svaki Ra je neovisno odabran od: H, C1-C4 alkila, -C(=O)H, -C(=O)(C1-C4 alkila), i -CO2(C1-C4 alkila).
7. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 6, naznačen time, što: R3 je neovisno odabran od: i ; svaki R3A je neovisno odabran od: halogena, CN, -(O)m-(C1-C4 alkila supstituiranog s 0-1 R3B), C1-C4 haloalkila, C1-C4 haloalkoksi, -C(=O)NH2, -C(=O)NH(C1-C4 alkila), -C(=O)N(C1-C4alkila)2, -C(=O)N(C1-C4 alkil)(CH2)2N(C1-C4 alkila)2, -CH2NHC(=O)(C1-C4alkila), -S(=O)2(C1-C4alkila), NH2, NH(C1-C4 alkila), N(C1-C4 alkila)2, C3-C6 cikloalkila,
i ; [0008] R3B je neovisno odabran od: OH, N(C1-C4 alkila)2, C1-C4 alkoksi, [0009] -C(=O)N(C1-C4 alkila)2, -S(=O)2(C1-C4 alkila),
i ; i svaki Ra je neovisno odabran od: H, C1-C4 alkila, -C(=O)H, -C(=O)(C1-C4 alkila), i -CO2(C1-C4 alkila).
8. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 7, naznačen time, što: svaki R3A je neovisno odabran od: F, Cl, CH3, -CH2OH, CH2F, CHF2, CF3, CN, -OCH3, -OCH2CH3, -OCH(CH3)2, -OCHF2, -C(=O)N(CH3)2, -CH2NHC(=O)CH3, -S(=O)2CH3, NH2, ciklopropila, i [0010] .
9. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 8, naznačen time, što je navedeni spoj predstavljen Formulom (IA-1): ili njegova farmaceutski prihvatljiva sol, gdje: R1 je neovisno H ili F; i R3A je neovisno odabran od: F, CH3, -CH2OH, CH2F, CHF2, CF3, i -OCH3.
10. Spoj prema zahtjevu 1 ili zahtjevu 2, naznačen time, što: R1 je neovisno H ili F; R2 je H; R3 je neovisno 5-člani heteroaril koji obuhvaća ugljikove atome i 1-4 heteroatoma koji su odabrani od N, NRa, O, i S(O)p; pri čemu je navedeni heteroaril supstituiran s 0-3 R3A; i Ra je neovisno odabran od: H, C1-C4 alkila supstituiranog s 0-1 Rb, -C(=O)H, -C(=O)(C1-C4 alkila), -CO2(C1-C4 alkila), C3-C6 cikloalkila, i benzila.
11. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1, 2 ili 10, naznačen time, što: R3 je neovisno odabran od: , , , , i .
12. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 11, naznačen time, što: R1 je F.
13. Spoj ili njegova farmaceutski prihvatljiva sol, prema zahtjevu 1, naznačen time, što je navedeni spoj odabran iz niza koji čine:
14. Spoj prema zahtjevu 1, naznačen time, što navedeni spoj je: [0011] , ili njegova farmaceutski prihvatljiva sol.
15. Spoj prema zahtjevu 1, naznačen time, što navedeni spoj je: [0012] , ili njegova farmaceutski prihvatljiva sol.
16. Spoj prema zahtjevu 1, naznačen time, što navedeni spoj je: [0013] , ili njegova farmaceutski prihvatljiva sol.
17. Spoj prema zahtjevu 1, naznačen time, što navedeni spoj je: [0014] , ili njegova farmaceutski prihvatljiva sol.
18. Spoj prema zahtjevu 1, naznačen time, što navedeni spoj je: [0015] , ili njegova farmaceutski prihvatljiva sol.
19. Spoj prema zahtjevu 1, naznačen time, što navedeni spoj je: [0016] , ili njegova farmaceutski prihvatljiva sol.
20. Farmaceutski pripravak, naznačen time, što obuhvaća jedan ili više farmaceutski prihvatljivih nosača i spoj ili njegovu farmaceutski prihvatljivu sol, prema bilo kojem od zahtjeva 1 do 19.
21. Farmaceutski pripravak prema zahtjevu 20, naznačen time, što nadalje obuhvaća najmanje jedno dodatno terapijsko sredstvo.
22. Farmaceutski pripravak prema zahtjevu 21, naznačen time, što je navedeno dodatno terapijsko sredstvo odabrano od drugih antikancerogenih sredstava, imunomodulatora, antialergijskih sredstava, antiemetika, sredstava za ublažavanje boli, citozaštitnih sredstava, i njihovih kombinacija.
23. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 19, naznačen time, što je za uporabu u terapiji.
24. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 19, za uporabu kao što je navedeno u patentnom zahtjevu 23, naznačen time, što je navedena terapija liječenje bolesti ili poremećaja posredovanog s EED i/ili PRC2.
25. Spoj ili njegova farmaceutski prihvatljiva sol, prema bilo kojem od zahtjeva 1 do 19, za uporabu kao što je navedeno u patentnom zahtjevu 24, naznačen time, što je navedena bolest odabrana ili je poremećaj odabran od difuznog limfoma velikih B-stanica, folikularnog limfoma, drugih limfoma, leukemije, multiplog mijeloma, mezotelioma, raka želuca, malignog rabdoidnog tumora, hepatocelularnog karcinoma, raka prostate, karcinoma dojke, karcinoma žučnih puteva i žučnog mjehura, karcinoma mjehura, tumora mozga uključujući neuroblastom, schwannom, gliom, glioblastom i astrocitom, raka grlića maternice, raka debelog crijeva, melanoma, raka endometrija, raka jednjaka, raka glave i vrata, raka pluća, nazofaringealnog karcinoma, raka jajnika, raka gušterače, karcinoma bubrežnih stanica, rektalnog raka, karcinoma štitnjače, paratiroidnih tumora, tumora maternice, sarkoma mekog tkiva.
26. Kombinacija, naznačena time, što se tvori od spoja ili njegove farmaceutski prihvatljive soli, prema bilo kojem od zahtjeva 1 do 19, i najmanje jednog dodatnog terapijskog sredstva.
27. Kombinacija prema zahtjevu 26, naznačena time, što je dodatno terapijsko sredstvo odabrano od drugih antikancerogenih sredstava, imunomodulatora, antialergijskih sredstava, antiemetika, sredstava za ublažavanje boli, citozaštitnih sredstava, i njihovih kombinacija.
HRP20190805TT 2014-12-23 2019-04-29 Spojevi triazolopirimidina i njihova uporaba HRP20190805T1 (hr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
CN2014094644 2014-12-23
CN2015095320 2015-11-23
PCT/IB2015/059843 WO2016103155A1 (en) 2014-12-23 2015-12-21 Triazolopyrimidine compounds and uses thereof
EP15820637.5A EP3237418B1 (en) 2014-12-23 2015-12-21 Triazolopyrimidine compounds and uses thereof

Publications (1)

Publication Number Publication Date
HRP20190805T1 true HRP20190805T1 (hr) 2019-06-28

Family

ID=55071101

Family Applications (1)

Application Number Title Priority Date Filing Date
HRP20190805TT HRP20190805T1 (hr) 2014-12-23 2019-04-29 Spojevi triazolopirimidina i njihova uporaba

Country Status (40)

Country Link
US (5) US10220036B2 (hr)
EP (1) EP3237418B1 (hr)
JP (1) JP6736559B2 (hr)
KR (1) KR102534028B1 (hr)
CN (1) CN107108637B (hr)
AU (1) AU2015370524B2 (hr)
BR (1) BR112017010354B8 (hr)
CA (1) CA2969090C (hr)
CL (1) CL2017001572A1 (hr)
CO (1) CO2017005992A2 (hr)
CR (1) CR20170285A (hr)
CY (1) CY1121901T1 (hr)
DK (1) DK3237418T3 (hr)
DO (1) DOP2017000149A (hr)
EA (1) EA032416B1 (hr)
EC (1) ECSP17047153A (hr)
ES (1) ES2722048T3 (hr)
GT (1) GT201700146A (hr)
HR (1) HRP20190805T1 (hr)
HU (1) HUE043060T2 (hr)
IL (1) IL252135B (hr)
JO (1) JO3489B1 (hr)
LT (1) LT3237418T (hr)
ME (1) ME03385B (hr)
MX (1) MX2017008529A (hr)
MY (1) MY186837A (hr)
NZ (1) NZ731664A (hr)
PE (1) PE20171307A1 (hr)
PH (1) PH12017501016A1 (hr)
PL (1) PL3237418T3 (hr)
PT (1) PT3237418T (hr)
RS (1) RS58679B1 (hr)
SG (1) SG11201703880VA (hr)
SI (1) SI3237418T1 (hr)
SV (1) SV2017005472A (hr)
TN (1) TN2017000204A1 (hr)
TW (1) TWI694076B (hr)
UA (1) UA120945C2 (hr)
UY (1) UY36462A (hr)
WO (1) WO2016103155A1 (hr)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY186837A (en) * 2014-12-23 2021-08-25 Novartis Ag Triazolopyrimidine compounds and uses thereof
WO2017210395A1 (en) * 2016-06-01 2017-12-07 Epizyme, Inc. Use of ezh2 inhibitors for treating cancer
CN109906224B (zh) * 2016-06-20 2022-02-25 诺华股份有限公司 三唑吡啶化合物及其应用
JP2019524872A (ja) * 2016-06-20 2019-09-05 ノバルティス アーゲー 癌の治療に有用なイミダゾピリミジン化合物
WO2017219948A1 (en) * 2016-06-20 2017-12-28 Novartis Ag Crystalline forms of triazolopyrimidine compound
TN2019000010A1 (en) 2016-07-12 2020-07-15 Revolution Medicines Inc 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors
CN106831601A (zh) * 2017-01-13 2017-06-13 河北博伦特药业有限公司 一种2‑氨基甲基嘧啶盐酸盐及其衍生物的合成方法
KR20190110588A (ko) 2017-01-23 2019-09-30 레볼루션 메디슨즈, 인크. 알로스테릭 shp2 억제제로서의 피리딘 화합물
AU2018210770B2 (en) 2017-01-23 2022-03-24 Revolution Medicines, Inc. Bicyclic compounds as allosteric SHP2 inhibitors
US10266542B2 (en) 2017-03-15 2019-04-23 Mirati Therapeutics, Inc. EZH2 inhibitors
WO2018170290A1 (en) * 2017-03-15 2018-09-20 Fulcrum Therapeutics, Inc. Compositions and methods for increasing fmr1 expression
US11312705B2 (en) * 2017-03-16 2022-04-26 Jiangsu Hengrui Medicine Co., Ltd. Heteroaryl[4,3-C]pyrimidine-5-amine derivative, preparation method therefor, and medical uses thereof
US11602529B2 (en) 2017-06-02 2023-03-14 Epizyme, Inc. Use of EZH2 inhibitors for treating cancer
CN109575013A (zh) * 2017-09-28 2019-04-05 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
WO2019062435A1 (zh) * 2017-09-28 2019-04-04 中国科学院上海药物研究所 三氮唑并嘧啶、三氮唑并吡啶化合物及其组合物用于治疗prc2介导的疾病
EP3694848A1 (en) 2017-10-12 2020-08-19 Revolution Medicines, Inc. Pyridine, pyrazine, and triazine compounds as allosteric shp2 inhibitors
CN109867645B (zh) * 2017-12-05 2021-09-14 中国医学科学院药物研究所 一种2,2-二氟-2,3-二氢取代苯并呋喃类化合物的合成方法
SG11202004090YA (en) 2017-12-15 2020-05-28 Revolution Medicines Inc Polycyclic compounds as allosteric shp2 inhibitors
CN109942556A (zh) * 2017-12-21 2019-06-28 上海青煜医药科技有限公司 嘧啶酮化合物及其应用
US11591312B2 (en) 2018-01-23 2023-02-28 Basf Se Halogenation of pyridine derivatives
KR102451529B1 (ko) 2018-01-31 2022-10-06 미라티 테라퓨틱스, 인크. Prc2 억제제
CN110156787B (zh) * 2018-02-13 2021-11-02 中国科学院上海药物研究所 一种三氮唑并嘧啶衍生化合物、包含其的药物组合物及其用途
CN110563722A (zh) * 2018-06-06 2019-12-13 上海青煜医药科技有限公司 吡啶或哒嗪并环化合物及其应用
CN110734436A (zh) * 2018-07-19 2020-01-31 上海青煜医药科技有限公司 嘧啶或吡嗪并环化合物及其应用
TW202039498A (zh) * 2018-11-30 2020-11-01 大陸商上海拓界生物醫藥科技有限公司 嘧啶並五員氮雜環類衍生物、其製備方法及其在醫藥上的應用
CN111518100A (zh) * 2019-02-02 2020-08-11 上海青煜医药科技有限公司 环丙烯并苯并呋喃取代的氮杂芳基化合物及其应用
BR112021018238A2 (pt) * 2019-03-15 2021-12-28 Fulcrum Therapeutics Inc Derivados de azolopiridina macrocíclicos como moduladores de eed e prc2
JP7299307B2 (ja) * 2019-04-03 2023-06-27 テラ・ストーン株式会社 チミン核酸塩基をベースとするトリアゾロピリミジン類及びその製造方法
WO2020219448A1 (en) * 2019-04-22 2020-10-29 Mirati Therapeutics, Inc. Naphthyridine derivatives as prc2 inhibitors
US11814734B2 (en) 2019-05-13 2023-11-14 Ecolab Usa Inc. 1,2,4-triazolo[1,5-a] pyrimidine derivative as copper corrosion inhibitor
CA3142711A1 (en) 2019-06-05 2020-12-10 Mirati Therapeutics, Inc. Imidazo[1,2-c]pyrimidine derivatives as prc2 inhibitors for treating cancer
EP3980021A4 (en) * 2019-06-05 2023-06-14 Atnx Spv, Llc METHODS OF TREATMENT AND/OR PREVENTION OF PSORIASIS
WO2021032004A1 (zh) * 2019-08-22 2021-02-25 上海青煜医药科技有限公司 氮杂芳基化合物及其应用
EP4034535A4 (en) * 2019-09-26 2023-11-22 Novartis AG AZACHINOLINE COMPOUNDS AND USES THEREOF
EP4056570A4 (en) * 2019-11-01 2023-12-20 ShanghaiTech University EED INHIBITOR AND PRODUCTION METHOD AND USE THEREOF
CN113004233B (zh) * 2019-12-18 2022-12-20 南京优氟医药科技有限公司 一种用于制备prc2抑制剂的化合物、其制备方法和用途
CN111333655B (zh) * 2020-04-13 2021-07-13 武汉工程大学 一种三唑并嘧啶类化合物及其制备方法和应用
WO2021228034A1 (en) * 2020-05-11 2021-11-18 Ascentage Pharma (Suzhou) Co., Ltd. Preparation method of (5-fluoro-2, 3-dihydrobenzofuran-4-yl) methanamine or its salt, and intermediates thereof
CA3185154A1 (en) 2020-05-28 2021-12-02 Novartis Ag Dosing regimens for n-((5-fluoro-2,3-dihydrobenzofuran-4-yl)methyl)-8-(2-methylpyridin-3-yl)-[1,2,4]triazolo[4,3-c]pyrimidin-5-amine, or a pharmaceutically acceptable salt thereof, for use in treating prc2-mediated diseases or disorders
CN114907385A (zh) 2021-02-10 2022-08-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
WO2023016511A1 (zh) * 2021-08-11 2023-02-16 上海青煜医药科技有限公司 氮杂芳基化合物、其制备方法及应用
CN117384153A (zh) * 2022-07-12 2024-01-12 上海赛岚生物科技有限公司 一类甲基转移酶抑制剂及其用途
WO2024215699A1 (en) * 2023-04-11 2024-10-17 Oric Pharmaceuticals, Inc. Treatment of t-cell lymphoma

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2779780A (en) 1955-03-01 1957-01-29 Du Pont 1, 4-diamino-2, 3-dicyano-1, 4-bis (substituted mercapto) butadienes and their preparation
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
IL143236A0 (en) 1998-12-16 2002-04-21 Warner Lambert Co Treatment of arthritis with mek inhibitors
NL1014106C2 (nl) 2000-01-18 2001-07-20 Univ Amsterdam Werkwijze voor het detecteren van een pathologische afwijking bij een cel, een antistof en een assay kit.
KR100773621B1 (ko) 2000-07-19 2007-11-05 워너-램버트 캄파니 엘엘씨 4-요오도 페닐아미노 벤즈히드록삼산의 산소화 에스테르
SE519662C2 (sv) * 2001-07-04 2003-03-25 Asept Int Ab Ventilanordning vid utportioneringsanordningar
AU2002357667A1 (en) * 2001-10-24 2003-05-06 Iconix Pharmaceuticals, Inc. Modulators of phosphoinositide 3-kinase
US6921762B2 (en) 2001-11-16 2005-07-26 Amgen Inc. Substituted indolizine-like compounds and methods of use
RU2334744C2 (ru) 2002-03-08 2008-09-27 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Макроциклические соединения, которые могут быть использованы в качестве фармацевтических препаратов
PL233493B1 (pl) 2002-03-13 2019-10-31 Array Biopharma Inc Związek benzoimidazolowy, jego zastosowanie oraz zawierająca go kompozycja farmaceutyczna
GB0228900D0 (en) 2002-12-11 2003-01-15 Ml Lab Plc Cancer Immunotherapy
JP2004238296A (ja) * 2003-02-04 2004-08-26 Kissei Pharmaceut Co Ltd 新規なトリアゾロピリミジン誘導体、それを含有する医薬組成物およびそれらの用途
EP1631260A2 (en) 2003-02-28 2006-03-08 Transform Pharmaceuticals, Inc. Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen
CA2528669A1 (en) 2003-06-09 2005-01-20 The Regents Of The University Of Michigan Compositions and methods for treating and diagnosing cancer
US20060246505A1 (en) 2003-09-02 2006-11-02 Reinhard Walther Modulation of the synthesis of insulin
ATE449168T1 (de) 2004-06-01 2009-12-15 Univ North Carolina Rekonstituierter histon-methyltransferase-komplex und verfahren zur identifizierung von modulatoren dafür
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
US7452892B2 (en) 2005-06-17 2008-11-18 Bristol-Myers Squibb Company Triazolopyrimidine cannabinoid receptor 1 antagonists
CA2618218C (en) 2005-07-21 2015-06-30 Ardea Biosciences, Inc. N-(arylamino)-sulfonamide inhibitors of mek
JO2660B1 (en) 2006-01-20 2012-06-17 نوفارتيس ايه جي Pi-3 inhibitors and methods of use
EP2041575A2 (en) 2006-03-31 2009-04-01 Ordway Research Institute Prognostic and diagnostic method for cancer therapy
WO2008083251A2 (en) 2006-12-27 2008-07-10 Usc Stevens - University Of Southern California Dna methylation markers based on epigenetic stem cell signatures in cancer
WO2009017670A2 (en) 2007-07-26 2009-02-05 University Of Massachusetts Ras-mediated epigenetic silencing effectors and uses thereof
EP2426108B1 (en) 2007-08-29 2016-08-10 MethylGene Inc. Processes and intermediates for preparing fused heterocyclic kinase inhibitors
BRPI0816769A2 (pt) 2007-09-12 2016-11-29 Hoffmann La Roche combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso
ES2439705T3 (es) 2007-10-25 2014-01-24 Genentech, Inc. Proceso para la preparación de compuestos de tienopirimidina
US8168784B2 (en) 2008-06-20 2012-05-01 Abbott Laboratories Processes to make apoptosis promoters
GB0822248D0 (en) 2008-12-05 2009-01-14 Medical Res Council Crystal meths
US8895526B2 (en) 2009-03-27 2014-11-25 Cold Spring Harbor Laboratory Identification of RNAI targets and use of RNAI for rational therapy of chemotherapy-resistant leukemia and other cancers
CN102020643A (zh) * 2009-09-22 2011-04-20 上海恒瑞医药有限公司 二氢喋啶酮类衍生物、其制备方法及其在医药上的应用
TW201200518A (en) 2010-03-10 2012-01-01 Kalypsys Inc Heterocyclic inhibitors of histamine receptors for the treatment of disease
US8536179B2 (en) * 2010-05-07 2013-09-17 Glaxosmithkline Llc Indoles
JP6389036B2 (ja) 2010-09-10 2018-09-12 エピザイム インコーポレイテッド ヒトｅｚｈ２の阻害剤、およびその使用方法
WO2012151277A1 (en) 2011-05-02 2012-11-08 Applied Informatic Solutions, Inc. Kits and methods for selecting a treatment for ovarian cancer
WO2013010181A2 (en) 2011-07-14 2013-01-17 University Of Massachusetts Methods of diagnosing cancer using epigenetic biomarkers
US9730925B2 (en) 2011-09-30 2017-08-15 Glaxomithkline Llc Methods of treating cancer
PL2825161T3 (pl) 2012-03-12 2019-06-28 Epizyme, Inc. Inhibitory ludzkiej ezh2 i sposoby ich zastosowania
JP2016500073A (ja) 2012-11-19 2016-01-07 ノバルティス アーゲー 寄生虫病の処置のための化合物および組成物
EP2934531A4 (en) 2012-12-19 2016-06-15 Glaxosmithkline Llc COMBINATION
US10047163B2 (en) 2013-02-08 2018-08-14 Abbvie Stemcentrx Llc Multispecific constructs
SG11201506077XA (en) 2013-02-11 2015-08-28 Constellation Pharmaceuticals Inc Modulators of methyl modifying enzymes, compositions and uses thereof
JP2016516046A (ja) 2013-03-14 2016-06-02 ジェネンテック， インコーポレイテッド がんの治療方法及びがん薬物耐性を阻止する方法
US9745305B2 (en) 2013-03-15 2017-08-29 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
WO2014144747A1 (en) * 2013-03-15 2014-09-18 Epizyme, Inc. Substituted 6,5-fused bicyclic heteroaryl compounds
ES2919024T3 (es) 2014-02-11 2022-07-21 Mitokinin Inc Composiciones y procedimientos que utilizan las mismas para el tratamiento de enfermedades neurodegenerativas y mitocondriales
MX2017006305A (es) 2014-11-14 2017-08-21 Basf Se Bencilpropargileter como inhibidores de la nitrificacion.
PT3033944T (pt) 2014-12-16 2018-05-14 Omya Int Ag Carbonato de cálcio para proteção de plantas
GB201501017D0 (en) 2014-12-23 2015-03-04 Immatics Biotechnologies Gmbh Novel peptides and combination of peptides for use in immunotherapy against hepatocellular carcinoma (HCC) and other cancers
MA41272A (fr) 2014-12-23 2017-10-31 Adama Makhteshim Ltd 5-fluoro-4-imino-3-(alkyle/alkyle substitué)-1-(arylsulfonyl)-3,4-dihydropyrimidin-2(1h)-one en tant que traitement des semences
MY186837A (en) * 2014-12-23 2021-08-25 Novartis Ag Triazolopyrimidine compounds and uses thereof

Also Published As

Publication number Publication date
SG11201703880VA (en) 2017-07-28
RS58679B1 (sr) 2019-06-28
US11207325B2 (en) 2021-12-28
SV2017005472A (es) 2018-06-12
BR112017010354A2 (pt) 2017-12-26
US20160176882A1 (en) 2016-06-23
IL252135B (en) 2020-06-30
CO2017005992A2 (es) 2017-10-20
JP6736559B2 (ja) 2020-08-05
CA2969090A1 (en) 2016-06-30
ECSP17047153A (es) 2019-02-28
AU2015370524B2 (en) 2018-11-01
GT201700146A (es) 2019-06-12
IL252135A0 (en) 2017-07-31
US20170348312A1 (en) 2017-12-07
CL2017001572A1 (es) 2018-01-12
ES2722048T3 (es) 2019-08-07
LT3237418T (lt) 2019-05-10
EP3237418A1 (en) 2017-11-01
TWI694076B (zh) 2020-05-21
US20190142837A1 (en) 2019-05-16
TN2017000204A1 (en) 2018-10-19
EP3237418B1 (en) 2019-01-30
KR20170095882A (ko) 2017-08-23
US20230033320A1 (en) 2023-02-02
MX2017008529A (es) 2017-10-25
TW201629065A (zh) 2016-08-16
US20200323859A1 (en) 2020-10-15
SI3237418T1 (sl) 2019-06-28
BR112017010354B1 (pt) 2022-09-20
PT3237418T (pt) 2019-05-23
JP2018500342A (ja) 2018-01-11
CY1121901T1 (el) 2020-10-14
PH12017501016B1 (en) 2017-12-11
EA201791420A1 (ru) 2017-10-31
NZ731664A (en) 2024-02-23
KR102534028B1 (ko) 2023-05-19
PH12017501016A1 (en) 2017-12-11
PL3237418T3 (pl) 2019-07-31
UY36462A (es) 2016-07-29
US11931363B2 (en) 2024-03-19
AU2015370524A1 (en) 2017-06-01
CN107108637B (zh) 2019-10-29
DOP2017000149A (es) 2017-07-15
ME03385B (me) 2020-01-20
DK3237418T3 (da) 2019-05-13
JO3489B1 (ar) 2020-07-05
CR20170285A (es) 2017-08-21
PE20171307A1 (es) 2017-09-05
US10220036B2 (en) 2019-03-05
EA032416B1 (ru) 2019-05-31
CA2969090C (en) 2023-05-02
HUE043060T2 (hu) 2019-07-29
US9580437B2 (en) 2017-02-28
CN107108637A (zh) 2017-08-29
MY186837A (en) 2021-08-25
UA120945C2 (uk) 2020-03-10
WO2016103155A1 (en) 2016-06-30
BR112017010354B8 (pt) 2022-10-18

Similar Documents

Publication Publication Date Title
HRP20190805T1 (hr) Spojevi triazolopirimidina i njihova uporaba
HRP20191826T4 (hr) Derivati n-piridinil acetamida kao inhibitori wnt signalnog puta
TN2015000102A1 (en) Bis(fluoroalkyl)-1,4-benzodiazepinone compounds as notch inhibitors
PH12017502246A1 (en) New hydroxyester derivatives, a process for their preparation and pharmaceutical compositions containing them
NZ626942A (en) New indolizine derivatives, method for preparing same and pharmaceutical compositions containing same
HRP20220864T1 (hr) Derivati n-piridinil acetamida kao inhibitori signalnog puta wnt
NZ630205A (en) Enhancer of zeste homolog 2 inhibitors
HRP20220886T1 (hr) Pripravci i postupci za proizvodnju pirimidina i spojeva piridina s btk inhibicijskom aktivnošću
PH12015501517A1 (en) Pyrimidone derivatives and their use in the treatment, amelioration or prevention of a viral disease
RU2015154275A (ru) Комбинации антитела против pd-l1 и ингибитора mek и/или ингибитора braf
HRP20170736T1 (hr) Indoli
JP2016512520A5 (hr)
MX2016001011A (es) Derivados de quinazolin-4-ona sustituida.
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MX2017008417A (es) Procedimientos para preparar inhibidores de cinasa 1 reguladora de señal de apoptosis (ask1).
PH12014502788B1 (en) ARYL SULTAM DERIVATIVES AS RORc MODULATORS
MX2014014106A (es) Derivados de acido 7-oxo-tiazolopiridinocarbonico y su uso en el tratamiento, disminucion o prevencion de una enfermedad viral.
NZ723772A (en) Neprilysin inhibitors
DOP2012000153A (es) Derivados de sulfonamida como agentes inductores de apoptosis con selectividad por bcl-2 para el tratamiento de cancer y enfermedades inmunes
TN2015000054A1 (en) Alkoxy pyrazoles as soluble guanylate cyclase activators
MX2014002208A (es) Inhibidores de serina/treonina quinasa.
AR066078A1 (es) Derivados de tetrahidroindol y tetrahidroindazol. procesos de obtencion, composiciones farmaceuticos y usos.
HRP20210158T1 (hr) Postupak i sustav za premještanje fluida iz posude za opskrbu u komponentu za isporuku
MX2015008288A (es) Derivados de piridona y su uso en el tratamiento, mejora o prevencion de una enfermedad viral.
MX2016008721A (es) Derivados de aril sultama como moduladores del receptor huerfano relacionado con acido retinoico (rorc).